BD First prescription for MET or SU among newly diagnosed type 2 diabetes Index date Day 0 First prescription of FDC or TPC within 120 days after BD Eligible base cohort entry date is between Jan 1 2002 and December 31 2013 ID: 935997
Download Presentation The PPT/PDF document "Base Cohort Entry Date" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Base Cohort Entry
Date* (BD)[First prescription for MET or SU among newly diagnosed type 2 diabetes
Index date† (Day 0)[First prescription of FDC or TPC within 120 days after BD]
*Eligible base cohort entry date is between Jan 1, 2002 and December 31, 2013†Index date was defined as the first prescription date of MET+SU or MET+DPP4i, either as FDC or TPC, among incident patients with type 2 diabetes.‡Earliest event: Outcomes of interest (individual outcome) or end of the study period (December 31, 2015).Abbreviations: AMI, acute myocardial infarction; ED, emergency department; FDC, fixed-dose combination; MET, metformin; TIA, transient ischemic attack; TPC, two-pill combination.
Inclusion criteria window Diagnosis of type 2 diabetes Days [-All data, 2013.12.31]
Washout Window (No antidiabetic drugs)Days [-365, BD-1]
Exclusion:
Death No TPC or FDC prescription Combinations not including MET + SU or MET+DPP4i Prescriptions including MET+DPP4i +SU Days [-BD,0]
Covariate assessment window: Gender, Age, Residence, Insurance quintile, Insurance type Days [0,0]
Follow up window
Days [0, Censor‡]
Primary OutcomeComposite of death or hospitalization with AMI, heart failure, or strokeSecondary Outcome:Individual component for secondary outcome
Time
Exclusion: Type 2 diabetes diagnosis Prescription with antidiabetics Aged < 18 years Hospitalization for stroke, TIA, heart failure, or AMI ED visit for stroke or TIA Days [-365, BD-1]
Exclusion: Type 1 diabetes diagnosis Days [-All data, All data]
Covariate assessment window: Smoking, Alcohol, BMI Days [-730,-1]
Covariate assessment window: Charlson comorbidity index, Comorbidities, Co-medication Days [-365,-1]
Supplemental Figure S1. Overview of study design